Search results for: 'AMI Infrastructure Developments across Asia'

01 Feb 2022  |  Global  |  Frost Radar

Frost Radar™: Global Enterprise Health Cloud Infrastructure and Platform Services, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The COVID-19 pandemic has revealed that many healthcare organizations have neither the agility and business continuity programs nor the technologies needed to support them during a crisis. Consequently, some have been forced to act on cloud and digital transformation strategies they had been delaying. The cloud has been critical in helping healthca...

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

In recent years, cybersecurity has become a priority for healthcare organizations. The healthcare sector is particularly affected by cyberattacks. Hospitals, healthcare organizations, patient databases, devices, and monitoring systems can be appetizing targets, destabilizing wider healthcare systems and affecting care delivery. The increasing adopt...

Asia-Pacific represents the fastest growing region for healthcare information technology (healthcare IT) solutions across the world. Rapidly changing demographic factors coupled with fast-moving government policies and legislations are allowing advanced IT tools to penetrate the market. These tools have the potential to change existing healthcare p...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Digitalization of the entire value chain will drive next-generation biomanufacturing. The industry is all set to move away from the traditional pen-and-paper-based process to a more advanced, digitized, track-and-trace process that is aligned toward Industry 4.0. Digital tools applied across processes, monitoring, analytics, and operations have acc...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...